Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Congenital Abnormalities 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cytarabine 34Filgrastim 14Idarubicin 13Etoposide 12Busulfan 12fludarabine phosphate 10Peripheral Blood Stem Cell Transplantation 10Cyclophosphamide 10Mitoxantrone 8Methotrexate 7Daunorubicin 7Cyclosporine 6Tacrolimus 5Radiotherapy 5Clofarabine 5Whole-Body Irradiation 4Mycophenolic Acid 4Gemtuzumab 4Arsenic Trioxide 4Antilymphocyte Serum 4Topotecan 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Decitabine 3eltrombopag 2choline magnesium trisalicylate 2aldesleukin 2Vorinostat 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myelomonocytic, Acute × trebananib × Clear all
NCT01555268 2022-09-13

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Completed
24 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡